Cargando…

The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles

BACKGROUND: Infertility remains a significant public health concern. An issue with controlled ovarian stimulation (COS) is the selection of an exogenous gonadotropin (Gn) regimen, which is mainly based on urinary follicle-stimulating hormone (uFSH), recombinant follicle-stimulating hormone alfa (rFS...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chunxia, Dong, Naijun, Li, Feng, Ji, Yurong, Pan, Yu, She, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210702/
https://www.ncbi.nlm.nih.gov/pubmed/35729654
http://dx.doi.org/10.1186/s13048-022-01009-w
_version_ 1784730211720364032
author Yang, Chunxia
Dong, Naijun
Li, Feng
Ji, Yurong
Pan, Yu
She, Hong
author_facet Yang, Chunxia
Dong, Naijun
Li, Feng
Ji, Yurong
Pan, Yu
She, Hong
author_sort Yang, Chunxia
collection PubMed
description BACKGROUND: Infertility remains a significant public health concern. An issue with controlled ovarian stimulation (COS) is the selection of an exogenous gonadotropin (Gn) regimen, which is mainly based on urinary follicle-stimulating hormone (uFSH), recombinant follicle-stimulating hormone alfa (rFSH-alfa), and human menopausal gonadotropin (HMG). In addition, most previous studies focused on the clinical pregnancy rates or live birth rates (LBR) per transfer cycle, but not on the cumulative live birth rate (CLBR) per started cycle. The CLBR, appears to be a more comprehensive and accurate universal measure of IVF treatment success. Therefore, this study aimed to compare the cumulative live birth rate (CLBR) between rFSH-alfa and uFSH regimens for ovarian stimulation. METHODS: This retrospective cohort study included patients who underwent assisted reproductive technology (ART) with gonadotropin-releasing hormone (GnRH) agonist long protocol between March 2009 and December 2018. Patients were grouped according to the Gn regimen received (rFSH-alfa or uFSH). The main outcome was CLBR, which defined as the first live birth following the use of all fresh and frozen embryos derived from a single COS cycle. RESULTS: A total of 1078 cycles were analyzed (314 with rFSH-alfa and 764 with uFSH). The rFSH-alfa group was characterized by a higher number of retrieved oocytes (13.3 vs. 11.0) and transferable embryos (5.0 vs. 4.0), a higher fresh embryo transfer rate (35.0% vs. 26.3%), and a higher multiple birth rate among the fresh embryo transfer cycles (8.2% vs. 2.5%) (P < 0.05). There were no differences in pregnancy rate (32.7% vs. 33.8%) and LBR (25.5% vs. 26.9%) per transfer cycle (P > 0.05). No significant difference was found in clinical outcomes among the frozen embryo transfer cycles (P > 0.05). The CLBR per started cycle in the rFSH-alfa group was higher than in the uFSH group (53.5% vs. 43.1%, P < 0.05). After adjustment, rFSH-alfa was independently associated with a higher CLBR (OR = 1.56; 95%CI = 1.18–2.05; P = 0.0018). CONCLUSIONS: rFSH-alfa and uFSH have similar pregnancy rates and LBR per transfer cycle, rFSH-alfa might achieve more transferrable blastocysts and higher CLBR per started cycle compared to uFSH. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-022-01009-w.
format Online
Article
Text
id pubmed-9210702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92107022022-06-22 The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles Yang, Chunxia Dong, Naijun Li, Feng Ji, Yurong Pan, Yu She, Hong J Ovarian Res Research BACKGROUND: Infertility remains a significant public health concern. An issue with controlled ovarian stimulation (COS) is the selection of an exogenous gonadotropin (Gn) regimen, which is mainly based on urinary follicle-stimulating hormone (uFSH), recombinant follicle-stimulating hormone alfa (rFSH-alfa), and human menopausal gonadotropin (HMG). In addition, most previous studies focused on the clinical pregnancy rates or live birth rates (LBR) per transfer cycle, but not on the cumulative live birth rate (CLBR) per started cycle. The CLBR, appears to be a more comprehensive and accurate universal measure of IVF treatment success. Therefore, this study aimed to compare the cumulative live birth rate (CLBR) between rFSH-alfa and uFSH regimens for ovarian stimulation. METHODS: This retrospective cohort study included patients who underwent assisted reproductive technology (ART) with gonadotropin-releasing hormone (GnRH) agonist long protocol between March 2009 and December 2018. Patients were grouped according to the Gn regimen received (rFSH-alfa or uFSH). The main outcome was CLBR, which defined as the first live birth following the use of all fresh and frozen embryos derived from a single COS cycle. RESULTS: A total of 1078 cycles were analyzed (314 with rFSH-alfa and 764 with uFSH). The rFSH-alfa group was characterized by a higher number of retrieved oocytes (13.3 vs. 11.0) and transferable embryos (5.0 vs. 4.0), a higher fresh embryo transfer rate (35.0% vs. 26.3%), and a higher multiple birth rate among the fresh embryo transfer cycles (8.2% vs. 2.5%) (P < 0.05). There were no differences in pregnancy rate (32.7% vs. 33.8%) and LBR (25.5% vs. 26.9%) per transfer cycle (P > 0.05). No significant difference was found in clinical outcomes among the frozen embryo transfer cycles (P > 0.05). The CLBR per started cycle in the rFSH-alfa group was higher than in the uFSH group (53.5% vs. 43.1%, P < 0.05). After adjustment, rFSH-alfa was independently associated with a higher CLBR (OR = 1.56; 95%CI = 1.18–2.05; P = 0.0018). CONCLUSIONS: rFSH-alfa and uFSH have similar pregnancy rates and LBR per transfer cycle, rFSH-alfa might achieve more transferrable blastocysts and higher CLBR per started cycle compared to uFSH. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-022-01009-w. BioMed Central 2022-06-21 /pmc/articles/PMC9210702/ /pubmed/35729654 http://dx.doi.org/10.1186/s13048-022-01009-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Chunxia
Dong, Naijun
Li, Feng
Ji, Yurong
Pan, Yu
She, Hong
The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
title The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
title_full The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
title_fullStr The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
title_full_unstemmed The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
title_short The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
title_sort cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210702/
https://www.ncbi.nlm.nih.gov/pubmed/35729654
http://dx.doi.org/10.1186/s13048-022-01009-w
work_keys_str_mv AT yangchunxia thecumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT dongnaijun thecumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT lifeng thecumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT jiyurong thecumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT panyu thecumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT shehong thecumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT yangchunxia cumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT dongnaijun cumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT lifeng cumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT jiyurong cumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT panyu cumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles
AT shehong cumulativelivebirthrateofrecombinantfolliclestimulatinghormonealfaverseurinaryhumanfolliclestimulatinghormoneforovarianstimulationinassistedreproductivetechnologycycles